Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd demonstrates a promising financial outlook driven by its innovative 3D bioprinting technology, particularly the rhCollagen-based bioink Collink.3D, which has shown superior performance in structured tissue formation compared to traditional materials. The recently operational U.S.-based logistics center is poised to enhance sales for both the BioInk and rhCollagen products, suggesting potential growth in revenue as adoption by research institutions increases. Additionally, strategic partnerships, including one with Allergan for dermal and soft tissue fillers, combined with upcoming clinical developments, highlight CollPlant's competitive edge in the regenerative medicine market and its relevance in advanced tissue engineering.

Bears say

CollPlant Biotechnologies Ltd's recent $2.0 million registered direct financing has raised concerns regarding its ability to effectively capitalize on favorable market conditions, thereby potentially undermining investor confidence. The pricing of shares at $1.25 suggests persistent downward pressure on the equity, limiting the company's capacity for future capital formation. Furthermore, lowered expectations for key product lines such as Dermal Fillers and BioInk, along with the removal of the Breast Implants program from financial forecasts, reflect a cautious outlook on revenue generation prospects.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.